Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Selected US clinical trials and emerging treatment strategies in MDS

Olatoyosi Odenike, MD, Duchossois Center for Advanced Medicine, Chicago, IL, discusses selected US clinical trials investigating emerging treatment strategies for myelodysplastic syndromes (MDS). Prof. Odenike highlights the myeloMATCH screening study (NCT05564390) and its molecularly targeted treatment trials, alongside developments in oral hypomethylating agents and the Phase III ELEMENT-MDS trial (NCT05949684) evaluating luspatercept in lower-risk MDS. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.